Dr. Reddy's shares dropped after the results for the third quarter of fiscal 2025 were released. While the earnings met expectations, the revenues exceeded them.
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #9MFY25--Dr. Reddy's Laboratories Ltd. has released its combined financial results for the quarter and the nine months that ended on December 31, 2024.
RDY has a solid position in the worldwide generics market because of its extensive range of generic drugs. Their work to improve their biosimilars collection is impressive.
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. has announced that it is launching Toripalimab in India.
Dr. Reddy's Laboratories Limited (NYSE:RDY) will hold its Q2 2025 Earnings Conference Call on November 5, 2024, at 9:00 AM ET. The call will feature company representatives, including Richa Periwal, the Head of Investor Relations, and Erez Israeli, the CEO. Participants will be in listen-only mode, but there will be a chance to ask questions after the presentation.
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's has entered into a voluntary licensing agreement with Gilead Sciences to produce and sell Lenacapavir in India and other nations.
Dr. Reddy's (RDY) is preparing to possibly work with Kainomyx to co-develop a cost-effective anti-malarial medication.
Since my last report, Dr. Reddy's Laboratories stock has increased by 29%, benefiting from new laws and strong business performance. The company maintains a strong competitive edge in the generics pharmaceutical sector, leading to consistently high returns on capital. Recent quarterly data indicates growth in the U.S., Europe, and India, suggesting an intrinsic value of $107 per share.
Erez Israeli from Dr. Reddy's Laboratories mentioned that the company is definitely looking to enter the biologics sector. He noted that although the U.S. is an important market, India and other regions are expected to grow at a quicker pace.
Dr. Reddy's (RDY) has released its first-quarter results for fiscal 2025, showing a mix of outcomes. While earnings fell short of expectations, revenues exceeded estimates due to an increase in global generics sales in North America and India.